Published in PLoS One on November 07, 2014
Pneumococcal nasopharyngeal carriage in children <5 years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel. Hum Vaccin Immunother (2016) 0.83
Reply to Farkouh RA et al. Comment on "Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-Typeable Haemophilus Influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children". Infect Dis Ther (2015) 0.79
Response to Wu et al. - Cost-effectiveness analysis of infant pneumococcal vaccination in Malaysia and Hong Kong. Hum Vaccin Immunother (2016) 0.77
Comment on: "Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children". Infect Dis Ther (2015) 0.76
Impact of ten-valent pneumococcal conjugate vaccine on pneumonia in Finnish children in a nation-wide population-based study. PLoS One (2017) 0.75
The impact of pneumococcal conjugate vaccine on community-acquired pneumonia hospitalizations in children with comorbidity. Eur J Pediatr (2017) 0.75
Prevention of Community-Acquired Pneumonia with Available Pneumococcal Vaccines. Int J Mol Sci (2016) 0.75
Effect of co-trimoxazole on mortality in HIV-exposed but uninfected children in Botswana (the Mpepu Study): a double-blind, randomised, placebo-controlled trial. Lancet Glob Health (2017) 0.75
External review and validation of the Swedish national inpatient register. BMC Public Health (2011) 11.28
U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med (2013) 6.60
Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet (2007) 5.50
Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis (2011) 5.31
Pneumonia: the leading killer of children. Lancet (2006) 3.66
Community-acquired pneumonia in children. N Engl J Med (2002) 3.50
Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio (2011) 2.48
National hospitalization trends for pediatric pneumonia and associated complications. Pediatrics (2010) 1.86
Pneumococcal vaccines WHO position paper - 2012 - recommendations. Vaccine (2012) 1.73
The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J (2012) 1.65
Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med (2007) 1.46
Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children. Clin Infect Dis (2014) 1.44
Effect of 10-valent pneumococcal vaccine on pneumonia among children, Brazil. Emerg Infect Dis (2013) 1.41
Reduction in hospitalizations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia. Pediatr Infect Dis J (2010) 1.39
Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on prevention of pneumonia. Pediatr Infect Dis J (2014) 1.23
Universal childhood immunisation against Streptococcus pneumoniae: the five-year experience of Liguria Region, Italy. Vaccine (2009) 1.23
Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua. Pediatr Infect Dis J (2014) 1.10
Significant decline in pneumonia admission rate after the introduction of routine 2+1 dose schedule heptavalent pneumococcal conjugate vaccine (PCV7) in children under 5 years of age in Kielce, Poland. Eur J Clin Microbiol Infect Dis (2010) 1.03
Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination. Expert Rev Vaccines (2011) 0.99
Hospitalized children with pneumonia in Uruguay: pre and post introduction of 7 and 13-valent pneumococcal conjugated vaccines into the National Immunization Program. Vaccine (2012) 0.91